Chronic Kidney Disease Market: Epidemiology, Therapies, Companies, DelveInsight | ProKidney, Reata Pharmaceuticals, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, KBP Biosciences, Kibow Pharma, Cincor

The Chronic Kidney Disease Therapeutics Market Size in the US was ~USD 2,824 million in 2023, which is further anticipated to increase during the forecast period.

Emerging therapies for Chronic Kidney Disease, including Ocedurenone (KBP-5074) and BI 690517 combined with Empagliflozin, are expected to drive significant growth in the Chronic Kidney Disease market in the coming years.

DelveInsight has released a new report titled "Chronic Kidney Disease - Market Insights, Epidemiology, and Market Forecast-2034", providing a comprehensive analysis of Chronic Kidney Disease, covering historical and projected epidemiology as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover about the Chronic Kidney Disease market report [https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

During the ERS Congress 2025 in September 2025, several biotechnology and pharmaceutical companies shared notable advancements in pulmonary and cardiopulmonary research:

*
In September 2025, Diagonal Therapeutics presented new preclinical data highlighting the potential of its lead clustering antibody, DIAG723, as a disease-modifying therapy for pulmonary arterial hypertension (PAH).

*
In September 2025, a study revealed that babies raised with dogs may have a reduced risk of developing childhood asthma.

*
In September 2025, Savara shared data from the Phase 3 IMPALA-2 trial of Molgramostim Inhalation Solution for patients with autoimmune pulmonary alveolar proteinosis (aPAP).

*
In September 2025, AllRock Bio, Inc. reported encouraging Phase 1 results for ROC-101, a first-in-class oral pan-ROCK inhibitor for cardiopulmonary and fibrotic diseases.

*
In September 2025, Gossamer Bio, Inc., in collaboration with Chiesi Group, announced five scientific presentations on seralutinib for PAH and PH-ILD.

*
In September 2025, Boehringer Ingelheim presented pooled analyses from the Phase III FIBRONEER Trademark program on nerandomilast, an investigational oral PDE4B inhibitor, showing a nominally significant reduction in mortality risk across IPF and PPF.

*
In September 2025, Kaia Health launched a pilot program of Kaia Breathe, a digital pulmonary rehabilitation solution for COPD patients, in partnership with MedImprove.

*
In September 2025, aTyr Pharma, Inc. shared additional findings from the Phase 3 EFZO-FIT Trademark study of efzofitimod in 268 patients with pulmonary sarcoidosis, a key form of interstitial lung disease.

Some of the key facts of the Chronic Kidney Disease Market Report:

*
In 2023, the Chronic Kidney Disease (CKD) therapeutics market in the United States was valued at around USD 2,824 million, with forecasts indicating continued growth through the projection period. The U.S. also had the highest CKD prevalence among the seven major markets (7MM), with approximately 40 million cases, a figure expected to rise by 2034, including about 2 million men and 3 million women.

*
Current CKD management involves erythropoietin-stimulating agents (ESAs), ACE inhibitors, ARBs, antidiabetic medications, secondary hyperparathyroidism (SHPT) therapies, and urate-lowering treatments, collectively accounting for USD 5,479 million across the 7MM in 2023. Market value is projected to increase with the introduction of novel therapies from 2024 to 2034.

*
In March 2023, Boehringer Ingelheim reported positive Phase II results for BI 690517, a selective aldosterone synthase inhibitor. When combined with empagliflozin, BI 690517 reduced albuminuria by up to 39.5% versus placebo, marking the first trial of this new class alongside standard-of-care therapy. These findings were highlighted at the American Society of Nephrology's Kidney Week 2023.

*
DelveInsight estimates that the number of diagnosed CKD cases across the 7MM was around 16 million in 2023, with the United States reporting the highest share (~5 million). Japan's CKD market reached USD 1,402 million in 2023 and is expected to expand significantly by 2034.

*
In March 2025, the FDA expanded Furoscix (furosemide injection) approval to treat edema in adults with CKD, including nephrotic syndrome, with availability expected by April 2025. In January 2025, the FDA approved semaglutide for reducing kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and CKD, as announced by Novo Nordisk.

*
Key companies shaping the CKD treatment landscape include ProKidney, Reata Pharmaceuticals, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica, Lexicon Pharmaceuticals, and Sanofi. Promising pipeline therapies include ONC 201, DSP-7888, AV-GBM-1, DB102, AB-218, and others.

Chronic Kidney Disease Overview

Chronic Kidney Disease (CKD) is a long-term, progressive disorder characterized by the gradual loss of kidney function. It is frequently associated with conditions like diabetes and hypertension, which can damage the blood vessels in the kidneys. Typical symptoms include fatigue, swelling (edema), and changes in urination patterns. CKD progresses through five stages, from mild kidney impairment in stage 1 to complete kidney failure, or end-stage renal disease (ESRD), in stage 5. Early detection through blood and urine tests is critical for managing the disease effectively and slowing its progression.

Chronic Kidney Disease Market Outlook

Management of Chronic Kidney Disease (CKD) focuses on slowing disease progression, relieving symptoms, and preventing complications. Central to care are lifestyle modifications, including following a kidney-friendly diet, engaging in regular exercise, and quitting smoking. Patients are often advised to limit salt, potassium, and protein intake to reduce strain on the kidneys.

Medications are also a cornerstone of CKD management. ACE inhibitors and angiotensin II receptor blockers (ARBs) are commonly used to control high blood pressure and reduce proteinuria, helping to slow kidney damage. Statins are prescribed to manage high cholesterol and lower the increased cardiovascular risk in CKD patients.

For CKD related to diabetes, blood sugar control is critical, with treatments such as metformin and SGLT2 inhibitors providing kidney-protective benefits. Anemia, frequently associated with CKD, is managed using erythropoiesis-stimulating agents (ESAs) and iron supplements.

In advanced CKD, when kidney function is severely impaired, renal replacement therapies such as hemodialysis and peritoneal dialysis are required to perform the kidneys' filtration functions. For end-stage renal disease (ESRD), a kidney transplant is the most effective option, necessitating ongoing immunosuppressive therapy to prevent organ rejection.

Overall, effective CKD care involves addressing underlying conditions like hypertension, diabetes, and high cholesterol, along with regular monitoring and timely treatment adjustments, to improve patient outcomes and quality of life.

Discover how the Chronic Kidney Disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Chronic Kidney Disease Marketed Drugs

*
KERENDIA (finerenone): Bayer HealthCare Pharmaceuticals Inc.

*
INVOKANA (canagliflozin): Janssen Research & Development, LLC

Chronic Kidney Disease Emerging Drugs

*
Ocedurenone (KBP-5074): KBP Biosciences

*
BI 690517 + Empagliflozin

Scope of the Chronic Kidney Disease Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Chronic Kidney Disease Companies: ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc., Lexicon Pharmaceuticals, Sanofi, and others

*
Chronic Kidney Disease Therapies: Ocedurenone (KBP-5074), BI 690517 + Empagliflozin, and others.

*
Chronic Kidney Disease Therapeutic Assessment: Chronic Kidney Disease current marketed and Chronic Kidney Disease emerging therapies

*
Chronic Kidney Disease Market Dynamics: Chronic Kidney Disease market drivers and Chronic Kidney Disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Chronic Kidney Disease Unmet Needs, KOL's views, Analyst's views, Chronic Kidney Disease Market Access and Reimbursement

To know what's more in our Chronic Kidney Disease report, visit https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Chronic Kidney Disease Market Report:

*
Chronic Kidney Disease market report covers a descriptive overview and comprehensive insight of the Chronic Kidney Disease Epidemiology and Chronic Kidney Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

*
The Chronic Kidney Disease market report provides insights into the current and emerging therapies.

*
The Chronic Kidney Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Chronic Kidney Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chronic Kidney Disease market.

Got queries? Click here to know more about the Chronic Kidney Disease market Landscape [https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Chronic Kidney Disease Patient Share (%) Overview at a Glance

5. Chronic Kidney Disease Market Overview at a Glance

6. Chronic Kidney Disease Disease Background and Overview

7. Chronic Kidney Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Kidney Disease

9. Chronic Kidney Disease Current Treatment and Medical Practices

10. Unmet Needs

11. Chronic Kidney Disease Emerging Therapies

12. Chronic Kidney Disease Market Outlook

13. Country-Wise Chronic Kidney Disease Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Chronic Kidney Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Chronic Kidney Disease Market Outlook 2034 [https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Related Reports:

Chronic Kidney Disease Pipeline Insights, DelveInsight

"Chronic Kidney Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Kidney Disease market. A detailed picture of the Chronic Kidney Disease pipeline landscape is provided, which includes the disease overview and Chronic Kidney Disease treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-kidney-disease-market-epidemiology-therapies-companies-delveinsight-prokidney-reata-pharmaceuticals-novo-nordisk-boehringer-ingelheim-eli-lilly-kbp-biosciences-kibow-pharma-cincor]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.